Daiichi says it’s ready to change the standard of care for acute myeloid leukemia — but it’s a work in progress
Close to 4 years ago, Daiichi Sankyo swooped in to buy little San Diego-based Ambit Biosciences for up to $410 million — $315 million of that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
